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Identity 
Other names: bHLHe37, N-myc, MODED, ODED 
HGNC (Hugo): MYCN 
Location: 2p24.3 





Fluorescence in-situ hybridization of MYCN probe to metaphase and interphase nuclei of a primary neuroblastoma with MYCN 
amplification (Courtesy Garrett M. Brodeur, Children's Hospital of Philadelphia). 
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464 amino acids; contains a phosphorylation site, an 
acidic domain, an HLH motif, and a leucine zipper in 
C-term; forms heterodimers with MAX and binds to an 
E-box DNA recognition sequence. The consensus 
sequence for the E-box element is CANNTG, with a 
palindromic canonical sequence of CACGTG. 
Expression 
MYCN is expressed in brain, eye, heart, kidney, lung, 
muscle, ovary, placenta and thymus.  
It is also expressed highly in several tumors: glioma, 
lung tumor, primitive neuroectodermal tumor, 




Probable transcription factor; possible role during 
tissue differentiation. 
Homology 




Amplification, either in extrachromosomal double 
minutes (DMs) or in homogeneously staining regions 
within chromosomes (there is amplification when, for 
example, 10 to 1000 copies of a gene are present in a 
cell); found amplified in a variety of human tumors, in 
particular in neuroblastoma and also in retinoblastoma, 
small cell lung carcinoma, astrocytoma; level of 
amplification related to the  
tumor progression; transgenic mice that overexpress 





Neuroblastoma karyotypes frequently reveal the 
cytogenetic hallmarks of gene amplification, namely 
DMs or HSRs. Schwab (Schwab et al., 1983) and Kohl 
(Kohl et al., 1983) originally identified the MYC-
related oncogene MYCN as the target of this 
amplification event.  
MYCN is located on the distal short arm of 
chromosome 2 (2p24), but in cells with MYCN 
amplification, the extra copies reside within these DMs 
or HSRs (Schwab et al., 1984).  
Additional genes may be coamplified with MYCN in a 
subset of cases (DDX1, NAG, ALK), but MYCN is the 
only gene that is consistently amplified from this locus. 
The magnitude of MYCN amplification varies, but it 
averages 100-200 copies per cell (range 5-500+ 
copies).The overall prevalence of MYCN amplification 
is 18-20%. Amplification of MYCN is associated with 
advanced stages of disease, unfavorable biological 
features, and a poor outcome (Brodeur et al., 1984; 
Seeger et al., 1985), but it is also associated with poor 
outcome in otherwise favorable patient groups (such as 
infants, and patients with lower stages of disease), 
underscoring its biological importance (Seeger et al., 
1985; Look et al., 1991; Tonini et al., 1997; 
Katzenstein et al., 1998; Bagatell et al., 2005; Georg  
et al., 2005; Schneiderman et al., 2008). Therefore, the  
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status of the MYCN gene is routinely determined from 
neuroblastoma samples obtained at diagnosis to assist 
in therapy planning (Look et al., 1991; Schwab et al., 
2004).  
Indeed, because of the dramatic degree of MYCN 
amplification and consequent overexpression in a 
subset of aggressive neuroblastomas, it should be an 
attractive therapeutic target (Pession and Tonelli, 2005; 
Bell et al., 2010).  
Weiss and colleagues (Weiss et al., 1997) created a 
transgenic mouse model of neuroblastoma, with 
MYCN expression driven in adrenergic cells by the 
tyrosine hydroxylase promoter (TH-MYCN mouse). 
Genomic changes in neuroblastomas arising in TH-
MYCN mice closely parallel the genomic changes 
found characteristically in human tumors (Hackett et 
al., 2003). Thus, the TH-MYCN mouse model appears 
to be a tractable model to study neuroblastoma 




MYCN amplification is less common in 
medulloblastoma, a neural brain tumor of childhood, 
but it is also associated with a worse clinical outc me 
(Pfister et al., 2009). However, recent evidence 
suggests that MYCN overexpression is much more 
common in medulloblastomas, compared to normal 
cerebellum (Swartling et al., 2010), and it may drive 
the initiation or progression of medulloblastomas 
independent of the sonic hedgehog (SHH) pathway. 
Indeed, MYCN amplification is found in both SHH-
driven and non-SHH-driven medulloblastomas, but 
each subtype is associated with other genetic featur s, 
suggesting they represent genetically distinct subtypes 
with different prognoses (Korshunov et al., 2011). 
Rhabdomyosarcoma (RMS) 
Note 
MYCN amplification also occurs in a subset of RMS, 
the most common pediatric soft tissue sarcoma, 
although it tends to be at a lower level (4-20 fold) than 
is found in neuroblastomas. Amplification is found 
predominantly in the alveolar subsest of RMS, and it is 
rarely found in the more common form, called 
embryonal RMS (Driman et al., 1994). However, 
MYCN expression is found in the vast majority of 
RMS tumors, regardless of histology, at least in 
primary tumors (Toffolatti et al., 2002). For this reason, 
Morgenstern and Anderson have suggested that it 
would be an attractive therapeutic target for this disease 
(Morgenstern and Anderson, 2006). 
Wilms tumor 
Note 
Wilms tumor may occasionally show amplification of 
the MYCN protooncogene (Schaub et al., 2007). 
MYCN amplification is consistently associated with 
overexpression, at least at the mRNA level. Initially, 
MYCN amplification was associated almost 
exclusively with the unfavorable, anaplastic subset of 
Wilms tumors. However, Williams and colleagues 
(Williams et al., 2011) found focal gain of MYCN ina 
substantial number of both anaplastic and favorable 
histologies in a survey of over 400 tumors, suggesting 
that other genomic changes may account for 
differences in clinical behavior. 
Other tumors (retinoblastoma, small cell 
lung cancer, glioblastoma multiforme) 
Note 
About 3-5% of primary retinoblastomas have MYCN 
amplification, whereas it is much more common (27%) 
in established retinoblastoma cell lines (Bowles et al., 
2007; Kim et al., 2008). MYCN is amplified in 15-25% 
of small cell lung cancers, and it may be more commn 
in tumors at relapse (Johnson et al., 1987; Johnson et 
al., 1992). MYCN amplification rarely occurs in other 
lung cancer histologies (Yokota et al., 1988). MYCN 
amplification occurs in a substantial number of 
glioblastoma multiformes (Hui et al., 2001; Hodgson et 
al., 2008), but it is rarely found in lower grade gliomas 
and astrocytomas. 
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